Story · Medicine & Biotech

Pelacarsen Fails to Reduce Cardiovascular Events Despite Lowering Lp(a): NEJM

1 outlet · first reported by Medical Dialogues on

USA: The Lp(a) HORIZON trial found that pelacarsen did not reduce major cardiovascular events in patients with elevated lipoprotein(a) and pre-existing cardiovascular disease. Over nearly five years, pelacarsen failed to significantly reduce the composite primary endpoint of cardiovascular death… (Medical Dialogues)

Coverage, in order

  1. Medical Dialogues India obscure peer-reviewed
    Pelacarsen Fails to Reduce Cardiovascular Events Despite Lowering Lp(a): NEJM

    USA: The Lp(a) HORIZON trial found that pelacarsen did not reduce major cardiovascular events in patients with elevated lipoprotein(a) and pre-existing cardiovascular disease. Over nearly five years, pelacarsen failed to significantly reduce the composite primary endpoint of cardiovascular death…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.